KMO and Parkinson disease: Decreasing production of neurotoxic metabolites such as 3-HK and QUIN with IDO, KMO, or KYNU inhibitors may reduce neuronal loss or atrophy in diseases like AD, PD, and HD, and may also offer promising therapy for MDD and HIV-associated neurocognitive disorder where neuroinflammation may contribute to the pathophysiology.